Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy (Review)

Matsuda,Satoru; Ichimura,Mayuko; Ogino,Mako; Nakano,Noriko; Minami,Akari; Murai,Toshiyuki; Kitagishi,Yasuko

doi:10.3892/ijo.2016.3710

Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy (Review)

Authors:
- Satoru Matsuda
- Mayuko Ichimura
- Mako Ogino
- Noriko Nakano
- Akari Minami
- Toshiyuki Murai
- Yasuko Kitagishi
View Affiliations

Affiliations: Department of Food Science and Nutrition, Nara Women's University, Kita-Uoya Nishimachi, Nara 630-8506, Japan, Department of Microbiology and Immunology and Department of Genome Biology, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan
Published online on: September 27, 2016 https://doi.org/10.3892/ijo.2016.3710
Pages: 1785-1790

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to the key role in various cellular processes including cell proliferation and cell survival on many cell types, dysregulation of the PI3K/AKT pathway represents a crucial step of the pathogenesis in many diseases. Furthermore, the tumor suppressor PTEN negatively regulates the PI3K/AKT pathway through its lipid phosphatase activity, which is recognized as one of the most frequently deleted and/or mutated genes in human cancer. Given the pervasive involvement of this pathway, the development of the molecules that modulate this PI3K/AKT signaling has been initiated in studies which focus on the extensive effective drug discovery. Consequently, the PI3K/AKT pathway appears to be an attractive pharmacological target both for cancer therapy and for neurological protection necessary after the therapy. A better understanding of the molecular relations could reveal new targets for treatment development. We review recent studies on the features of PI3K/AKT and PTEN, and their pleiotropic functions relevant to the signaling pathways involved in cancer progress and in neuronal damage by the therapy.

View Figures

View References

1	Lee JJ, Loh K and Yap YS: PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 12:342–354. 2015.
2	Robbins HL and Hague A: The PI3K/Akt pathway in tumors of endocrine tissues. Front Endocrinol (Lausanne). 6:1882016.
3	Faes S and Dormond O: PI3K and AKT: Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015. View Article : Google Scholar : PubMed/NCBI
4	Gesmundo I, Villanova T, Gargantini E, Arvat E, Ghigo E and Granata R: The mineralocorticoid agonist fludrocortisone promotes survival and proliferation of adult hippocampal progenitors. Front Endocrinol (Lausanne). 7:662016.
5	Wahane SD, Hellbach N, Prentzell MT, Weise SC, Vezzali R, Kreutz C, Timmer J, Krieglstein K, Thedieck K and Vogel T: PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2. J Neurochem. 130:255–267. 2014. View Article : Google Scholar : PubMed/NCBI
6	Simper NB, Jones CL, MacLennan GT, Montironi R, Williamson SR, Osunkoya AO, Wang M, Zhang S, Grignon DJ, Eble JN, et al: Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. Hum Pathol. 46:805–812. 2015. View Article : Google Scholar : PubMed/NCBI
7	Fallahabadi ZR, Noori Daloii MR, Mahdian R, Behjati F, Shokrgozar MA, Abolhasani M, Asgari M and Shahrokh H: Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer. Gene. 575:755–760. 2016. View Article : Google Scholar
8	Collaud S, Tischler V, Atanassoff A, Wiedl T, Komminoth P, Oehlschlegel C, Weder W and Soltermann A: Lung neuroendocrine tumors: Correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. BMC Cancer. 15:742015. View Article : Google Scholar : PubMed/NCBI
9	Chen SY, Zheng XW, Cai JX, Zhang WP, You HS, Xing JF and Dong YL: Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer. Int J Oncol. 49:294–304. 2016.PubMed/NCBI
10	Sinagra T, Tamburella A, Urso V, Siarkos I, Drago F, Bucolo C and Salomone S: Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells. Biochem Pharmacol. 85:551–559. 2013. View Article : Google Scholar
11	Day J, Gillespie DC, Rooney AG, Bulbeck HJ, Zienius K, Boele F and Grant R: Neurocognitive deficits and neurocognitive rehabilitation in adult brain tumors. Curr Treat Options Neurol. 18:222016. View Article : Google Scholar : PubMed/NCBI
12	Cheung YT and Krull KR: Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review. Neurosci Biobehav Rev. 53:108–120. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zheng Q, Yang L, Tan LM, Qin LX, Wang CY and Zhang HN: Stroke-like migraine attacks after radiation therapy syndrome. Chin Med J (Engl). 128:2097–2101. 2015. View Article : Google Scholar
14	Ricard D, Taillia H and Renard JL: Brain damage from anticancer treatments in adults. Curr Opin Oncol. 21:559–565. 2009. View Article : Google Scholar : PubMed/NCBI
15	Goh CP, Putz U, Howitt J, Low LH, Gunnersen J, Bye N, Morganti-Kossmann C and Tan SS: Nuclear trafficking of Pten after brain injury leads to neuron survival not death. Exp Neurol. 252:37–46. 2014. View Article : Google Scholar
16	Qin J, Xie Y, Wang B, Hoshino M, Wolff DW, Zhao J, Scofield MA, Dowd FJ, Lin MF and Tu Y: Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene. 28:1853–1863. 2009. View Article : Google Scholar : PubMed/NCBI
17	Chen F, Chen X, Yang D, Che X, Wang J, Li X, Zhang Z, Wang Q, Zheng W, Wang L, et al: Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways. Oncol Rep. 36:165–172. 2016.PubMed/NCBI
18	Zhang J, Yu XH, Yan YG, Wang C and Wang WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
19	Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L and Vitale G: PI3K/Akt/mTOR signaling in medullary thyroid cancer: A promising molecular target for cancer therapy. Endocrine. 48:363–370. 2015. View Article : Google Scholar
20	Goschzik T, Gessi M, Denkhaus D and Pietsch T: PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region. J Neuropathol Exp Neurol. 73:747–751. 2014. View Article : Google Scholar : PubMed/NCBI
21	Han X, Ji Y, Zhao J, Xu X and Lou W: Expression of PTEN and mTOR in pancreatic neuroendocrine tumors. Tumour Biol. 34:2871–2879. 2013. View Article : Google Scholar : PubMed/NCBI
22	Lee M, Wiedemann T, Gross C, Leinhäuser I, Roncaroli F, Braren R and Pellegata NS: Targeting PI3K/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. Clin Cancer Res. 21:3204–3215. 2015. View Article : Google Scholar : PubMed/NCBI
23	Bony C, Roche S, Shuichi U, Sasaki T, Crackower MA, Penninger J, Mano H and Pucéat M: A specific role of phosphatidylinositol 3-kinase gamma. A regulation of autonomic Ca²⁺ oscillations in cardiac cells. J Cell Biol. 152:717–728. 2001. View Article : Google Scholar : PubMed/NCBI
24	Yanamandra M, Mitra S and Giri A: Development and application of PI3K assays for novel drug discovery. Expert Opin Drug Discov. 10:171–186. 2015. View Article : Google Scholar
25	Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B and Ribas A: Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer. 13:832014. View Article : Google Scholar : PubMed/NCBI
26	Schilling T and Eder C: Stimulus-dependent requirement of ion channels for microglial NADPH oxidase-mediated production of reactive oxygen species. J Neuroimmunol. 225:190–194. 2010. View Article : Google Scholar : PubMed/NCBI
27	Clark LF and Kodadek T: The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer's disease, Parkinson's disease, and Huntington's disease. ACS Chem Neurosci. 7:520–527. 2016. View Article : Google Scholar : PubMed/NCBI
28	Lam M, Oleinick NL and Nieminen AL: Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells. Reactive oxygen species and mitochondrial inner membrane permeabilization. J Biol Chem. 276:47379–47386. 2001. View Article : Google Scholar : PubMed/NCBI
29	Zhu Y, Hoell P, Ahlemeyer B, Sure U, Bertalanffy H and Krieglstein J: Implication of PTEN in production of reactive oxygen species and neuronal death in in vitro models of stroke and Parkinson's disease. Neurochem Int. 50:507–516. 2007. View Article : Google Scholar
30	Lim HJ, Crowe P and Yang JL: Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol. 141:671–689. 2015. View Article : Google Scholar
31	Kitagishi Y and Matsuda S: Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute to neuroprotection in a traumatic brain injury. Alzheimers Res Ther. 5:422013. View Article : Google Scholar : PubMed/NCBI
32	Liu NK and Xu XM: Neuroprotection and its molecular mechanism following spinal cord injury. Neural Regen Res. 7:2051–2062. 2012.PubMed/NCBI
33	Cheng B, Martinez AA, Morado J, Scofield V, Roberts JL and Maffi SK: Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway. Neurochem Int. 62:31–42. 2013. View Article : Google Scholar
34	Ermak G, Hench KJ, Chang KT, Sachdev S and Davies KJ: Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro. J Biol Chem. 284:11845–11853. 2009. View Article : Google Scholar : PubMed/NCBI
35	Walker CL, Liu NK and Xu XM: PTEN/PI3K and MAPK signaling in protection and pathology following CNS injuries. Front Biol (Beijing). 8:421–433. 2013. View Article : Google Scholar
36	Delgado-Esteban M, Martin-Zanca D, Andres-Martin L, Almeida A and Bolaños JP: Inhibition of PTEN by peroxynitrite activates the phosphoinositide-3-kinase/Akt neuroprotective signaling pathway. J Neurochem. 102:194–205. 2007. View Article : Google Scholar : PubMed/NCBI
37	Takeuchi K, Gertner MJ, Zhou J, Parada LF, Bennett MV and Zukin RS: Dysregulation of synaptic plasticity precedes appearance of morphological defects in a Pten conditional knockout mouse model of autism. Proc Natl Acad Sci USA. 110:4738–4743. 2013. View Article : Google Scholar : PubMed/NCBI
38	Li W, Huang R, Chen Z, Yan LJ, Simpkins JW and Yang SH: PTEN degradation after ischemic stroke: A double-edged sword. Neuroscience. 274:153–161. 2014. View Article : Google Scholar : PubMed/NCBI
39	Sun F, Park KK, Belin S, Wang D, Lu T, Chen G, Zhang K, Yeung C, Feng G, Yankner BA, et al: Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature. 480:372–375. 2011. View Article : Google Scholar : PubMed/NCBI
40	Li Y, Low LH, Putz U, Goh CP, Tan SS and Howitt J: Rab5 and Ndfip1 are involved in Pten ubiquitination and nuclear trafficking. Traffic. 15:749–761. 2014. View Article : Google Scholar : PubMed/NCBI
41	Mandelblatt JS, Hurria A, McDonald BC, Saykin AJ, Stern RA, VanMeter JW, McGuckin M, Traina T, Denduluri N, Turner S, et al; Thinking and Living With Cancer Study. Cognitive effects of cancer and its treatments at the intersection of aging: What do we know; what do we need to know? Semin Oncol. 40:709–725. 2013. View Article : Google Scholar : PubMed/NCBI
42	Evenden J: Cognitive impairments and cancer chemotherapy: Translational research at a crossroads. Life Sci. 93:589–595. 2013. View Article : Google Scholar : PubMed/NCBI
43	Walker CL and Xu XM: PTEN inhibitor bisperoxovanadium protects oligodendrocytes and myelin and prevents neuronal atrophy in adult rats following cervical hemicontusive spinal cord injury. Neurosci Lett. 573:64–68. 2014. View Article : Google Scholar : PubMed/NCBI
44	Khalil B, El Fissi N, Aouane A, Cabirol-Pol MJ, Rival T and Liévens JC: PINK1-induced mitophagy promotes neuroprotection in Huntington's disease. Cell Death Dis. 6:e16172015. View Article : Google Scholar : PubMed/NCBI
45	Ozaita A, Puighermanal E and Maldonado R: Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem. 102:1105–1114. 2007. View Article : Google Scholar : PubMed/NCBI
46	Li S, Zhou Y, Wang R, Zhang H, Dong Y and Ip C: Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther. 6:1031–1038. 2007. View Article : Google Scholar : PubMed/NCBI
47	Hui J, Zhang J, Kim H, Tong C, Ying Q, Li Z, Mao X, Shi G, Yan J, Zhang Z, et al: Fluoxetine regulates neurogenesis in vitro through modulation of GSK-3β/β-catenin signaling. Int J Neuropsychopharmacol. 18:pyu0992014. View Article : Google Scholar
48	Park SW, Phuong VT, Lee CH, Lee JG, Seo MK, Cho HY, Fang ZH, Lee BJ and Kim YH: Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress. Neurosci Res. 71:335–340. 2011. View Article : Google Scholar : PubMed/NCBI
49	Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M and Gogos JA: Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 36:131–137. 2004. View Article : Google Scholar : PubMed/NCBI
50	Kozlovsky N, Amar S, Belmaker RH and Agam G: Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol. 9:337–342. 2006. View Article : Google Scholar
51	Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y and Lee YH: The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 34:2080–2089. 2013. View Article : Google Scholar : PubMed/NCBI
52	Liu KJ, Lee YL, Yang YY, Shih NY, Ho CC, Wu YC, Huang TS, Huang MC, Liu HC, Shen WW, et al: Modulation of the development of human monocyte-derived dendritic cells by lithium chloride. J Cell Physiol. 226:424–433. 2011. View Article : Google Scholar
53	Wu J, Li J, Hu H, Liu P, Fang Y and Wu D: Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. Cell Mol Neurobiol. 32:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
54	Liu B, Li L, Zhang Q, Chang N, Wang D, Shan Y, Li L, Wang H, Feng H, Zhang L, et al: Preservation of GABAA receptor function by PTEN inhibition protects against neuronal death in ischemic stroke. Stroke. 41:1018–1026. 2010. View Article : Google Scholar : PubMed/NCBI
55	Cai J, Yi Z, Lu W, Fang Y and Zhang C: Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction. Med Hypotheses. 80:486–489. 2013. View Article : Google Scholar : PubMed/NCBI
56	Mirones I, Angel Rodríguez-Milla M, Cubillo I, Mariñas-Pardo L, de la Cueva T, Zapata A, González C, Ramírez M and García-Castro J: Dopamine mobilizes mesenchymal progenitor cells through D2-class receptors and their PI3K/AKT pathway. Stem Cells. 32:2529–2538. 2014. View Article : Google Scholar : PubMed/NCBI
57	Stavarache MA, Musatov S, McGill M, Vernov M and Kaplitt MG: The tumor suppressor PTEN regulates motor responses to striatal dopamine in normal and Parkinsonian animals. Neurobiol Dis. 82:487–494. 2015. View Article : Google Scholar : PubMed/NCBI
58	Souza BR, Romano-Silva MA and Tropepe V: Dopamine D2 receptor activity modulates Akt signaling and alters GABAergic neuron development and motor behavior in zebrafish larvae. J Neurosci. 31:5512–5525. 2011. View Article : Google Scholar : PubMed/NCBI
59	Walker CL, Walker MJ, Liu NK, Risberg EC, Gao X, Chen J and Xu XM: Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PLoS One. 7:e300122012. View Article : Google Scholar : PubMed/NCBI
60	Mao D and Sun X: Reactivation of the PI3K/Akt signaling pathway by the bisperoxovanadium compound bpV(pic) attenuates photoreceptor apoptosis in experimental retinal detachment. Invest Ophthalmol Vis Sci. 56:5519–5532. 2015. View Article : Google Scholar : PubMed/NCBI
61	Spinelli L, Lindsay YE and Leslie NR: PTEN inhibitors: an evaluation of current compounds. Adv Biol Regul. 57:102–111. 2015. View Article : Google Scholar
62	Tian HY, Li ZX, Li HY, Wang HJ, Zhu XW and Dou ZH: Effects of 14 single herbs on the induction of caspase-3 in tumor cells: A brief review. Chin J Integr Med. 19:636–640. 2013. View Article : Google Scholar : PubMed/NCBI
63	Traka MH, Spinks CA, Doleman JF, Melchini A, Ball RY, Mills RD and Mithen RF: The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer. Mol Cancer. 9:1892010. View Article : Google Scholar : PubMed/NCBI
64	de la Parra C, Castillo-Pichardo L, Cruz-Collazo A, Cubano L, Redis R, Calin GA and Dharmawardhane S: Soy isoflavone genistein-mediated downregulation of miR-155 contributes to the anticancer effects of genistein. Nutr Cancer. 68:154–164. 2016. View Article : Google Scholar : PubMed/NCBI
65	Kwon OJ, Zhang B, Zhang L and Xin L: High fat diet promotes prostatic basal-to-luminal differentiation and accelerates initiation of prostate epithelial hyperplasia originated from basal cells. Stem Cell Res (Amst). 16:682–691. 2016. View Article : Google Scholar
66	Aronchik I, Kundu A, Quirit JG and Firestone GL: The antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradation. Mol Cancer Res. 12:1621–1634. 2014. View Article : Google Scholar : PubMed/NCBI
67	Eason RR, Velarde MC, Chatman L Jr, Till SR, Geng Y, Ferguson M, Badger TM and Simmen RC: Dietary exposure to whey proteins alters rat mammary gland proliferation, apoptosis, and gene expression during postnatal development. J Nutr. 134:3370–3377. 2004.PubMed/NCBI
68	Rovito D, Giordano C, Vizza D, Plastina P, Barone I, Casaburi I, Lanzino M, De Amicis F, Sisci D, Mauro L, et al: Omega-3 PUFA ethanolamides DHEA and EPEA induce autophagy through PPARγ activation in MCF-7 breast cancer cells. J Cell Physiol. 228:1314–1322. 2013. View Article : Google Scholar
69	Ghosh-Choudhury T, Mandal CC, Woodruff K, St Clair P, Fernandes G, Choudhury GG and Ghosh-Choudhury N: Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat. 118:213–228. 2009. View Article : Google Scholar
70	Moreira JD, Knorr L, Thomazi AP, Simão F, Battú C, Oses JP, Gottfried C, Wofchuk S, Salbego C, Souza DO, et al: Dietary omega-3 fatty acids attenuate cellular damage after a hippocampal ischemic insult in adult rats. J Nutr Biochem. 21:351–356. 2010. View Article : Google Scholar
71	Yu H, Deng J and Zuo Z: High-fat diet reduces neuroprotection of isoflurane post-treatment: Role of carboxyl-terminal modulator protein-Akt signaling. Obesity (Silver Spring). 22:2396–2405. 2014. View Article : Google Scholar
72	Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K and Eucker J: Anti-tumor effect of honokiol alone and in combination with other anticancer agents in breast cancer. Eur J Pharmacol. 591:43–51. 2008. View Article : Google Scholar : PubMed/NCBI
73	Xian YF, Ip SP, Mao QQ, Su ZR, Chen JN, Lai XP and Lin ZX: Honokiol improves learning and memory impairments induced by scopolamine in mice. Eur J Pharmacol. 760:88–95. 2015. View Article : Google Scholar : PubMed/NCBI
74	Wong TF, Takeda T, Li B, Tsuiji K, Kitamura M, Kondo A and Yaegashi N: Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition. Gynecol Oncol. 122:141–148. 2011. View Article : Google Scholar : PubMed/NCBI
75	Cao F, Liu T, Xu Y, Xu D and Feng S: Curcumin inhibits cell proliferation and promotes apoptosis in human osteoclastoma cell through MMP-9, NF-κB and JNK signaling pathways. Int J Clin Exp Pathol. 8:6037–6045. 2015.
76	Hoppe JB, Coradini K, Frozza RL, Oliveira CM, Meneghetti AB, Bernardi A, Pires ES, Beck RC and Salbego CG: Free and nano-encapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: Involvement of BDNF and Akt/GSK-3β signaling pathway. Neurobiol Learn Mem. 106:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
77	Yoshida H, Okumura N, Kitagishi Y, Nishimura Y and Matsuda S: Ethanol extract of Rosemary repressed PTEN expression in K562 culture cells. Int J appl Biol Pharm Technol. 2:316–322. 2011.
78	Choi SY, Kim YO, Son D, Lee J, Kim S, Kim H, Kim S and Hur J: 3-[2-(3,5-Dimethoxyphenyl)vinyl]furan protects hippocampal neurons against ischemic damage. Brain Res. 1472:32–37. 2012. View Article : Google Scholar : PubMed/NCBI
79	Tedeschi PM, Kathari YK, Farooqi IN and Bertino JR: Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts. Cancer Chemother Pharmacol. 74:1029–1032. 2014. View Article : Google Scholar : PubMed/NCBI